Senior Correspondent, London
Ben's Feed
Oct 2, 2014

EU agency adopts plan to cut clinical trial secrecy

LONDON, Oct 2 (Reuters) – Europe’s medicines regulator has
endorsed a scheme to publish detailed clinical reports
underpinning new drug approvals from next year, though
campaigners for full transparency said they were concerned some
data would still be missing.

The London-based European Medicines Agency (EMA) has been at
the centre of a row about divulging trials data for the past two
years, following concerns over undisclosed data for certain
drugs such as Roche’s flu pill Tamiflu.

Oct 2, 2014
Oct 1, 2014
Oct 1, 2014
Oct 1, 2014
Oct 1, 2014
Sep 30, 2014
Sep 30, 2014

New cancer therapy comes of age, cost a “toxic” side effect

MADRID (Reuters) – A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects — but their high cost is a growing concern.

Drugs that help the body’s own immune cells fight tumors are expected to be used in multi-drug cocktails, pushing the price of therapies costing more than $100,000 a year even higher.

Sep 30, 2014
Sep 29, 2014

Roche, GSK melanoma pill combinations look similar in showdown

MADRID, Sept 29 (Reuters) – Rival two-pill combinations for
melanoma from Roche and GlaxoSmithKline had
similarly good results in separate clinical trials, leaving
doctors with little to choose between the two skin cancer
courses.

The latest findings will fuel a wider debate about the
optimal treatment of melanoma as a new generation of
immune-stimulating injections offers an alternative way to fight
the deadliest form of skin cancer.

    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben